Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

HC Wainwright & Co. Maintains Buy on Checkpoint Therapeutics, Lowers Price Target to $20

Author: Benzinga Newsdesk | August 12, 2024 03:45pm
HC Wainwright & Co. analyst Joseph Pantginis maintains Checkpoint Therapeutics (NASDAQ:CKPT) with a Buy and lowers the price target from $34 to $20.

Posted In: CKPT

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist